Paid Clinical Trials Killeen

Discover 672 paid clinical trials in Killeen, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 672

FeaturedActive & Responsive

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

for

Moderately to Severely Active Ulcerative Colitis

Location: Temple TX, Georgetown TX, Mansfield TX, San Antonio TX,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06588855

Phase3, Recruiting

FeaturedActive & Responsive

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for

Moderately to Severely Active Crohns Disease

Location: Temple TX, Georgetown TX, Mansfield TX, Arlington TX,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06819878

Phase3, Recruiting

FeaturedActive & Responsive

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

for

Geographic Atrophy

Location: Austin TX, Bellaire TX, St Louis MO, Nashville TN,

Sponsor: Genentech, Inc.

Sex: All

Age: 50+

Code: NCT05626114

Phase2, Recruiting

Featured

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for

B-Cell Non-Hodgkins Lymphoma

Location: Temple TX, The Woodlands TX, Tyler TX, Baton Rouge LA,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06806033

Phase2, Recruiting

Featured

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

for

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis,

Location: Georgetown TX, Waco TX, Austin TX, Fort Worth TX,

Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06318169

Phase3, Recruiting

Featured

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

for

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis,

Location: Georgetown TX, Waco TX, Austin TX, San Marcos TX,

Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06419374

Phase3, Recruiting

Featured

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

for

Parkinson's Disease

Location: Round Rock TX, Dallas TX, Tulsa OK, Memphis TN,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 50 - 70+

Code: NCT07174310

Phase3, Recruiting

Featured

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

for

Diabetic Macular Edema

Location: Austin TX, San Antonio TX, Abilene TX, Germantown TN,

Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07425522

Phase1, Recruiting

Featured

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

for

Neovascular Age-related Macular Degeneration

Location: Austin TX, Schertz TX, Bellaire TX, Germantown TN,

Sponsor: Genentech, Inc.

Sex: All

Age: 50+

Code: NCT04853251

Recruiting

Featured

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer,

Location: Austin TX, Irving TX, Germantown TN, Kansas City MO,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06065748

Phase3, Recruiting

Paid Clinical Trials Killeen

Filter results

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Interested in new trials?

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)